Advancing regulatory science for medical countermeasure development: workshop summary
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
Natlional Academies Press
©2011
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Description based on print version record |
| Beschreibung: | 1 online resource (xviii, 132 pages) illustrations |
| ISBN: | 0309214904 0309214912 1283253542 9780309214902 9780309214919 9781283253543 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043039347 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151120s2011 |||| o||u| ||||||eng d | ||
| 020 | |a 0309214904 |9 0-309-21490-4 | ||
| 020 | |a 0309214912 |c electronic bk. |9 0-309-21491-2 | ||
| 020 | |a 1283253542 |9 1-283-25354-2 | ||
| 020 | |a 9780309214902 |9 978-0-309-21490-2 | ||
| 020 | |a 9780309214919 |c electronic bk. |9 978-0-309-21491-9 | ||
| 020 | |a 9781283253543 |9 978-1-283-25354-3 | ||
| 035 | |a (OCoLC)748588094 | ||
| 035 | |a (DE-599)BVBBV043039347 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 362.18 |2 23 | |
| 245 | 1 | 0 | |a Advancing regulatory science for medical countermeasure development |b workshop summary |c Theresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Forum on Medical and Public Health PreparadnessforCatastropicEvents, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| 264 | 1 | |a Washington, D.C. |b Natlional Academies Press |c ©2011 | |
| 300 | |a 1 online resource (xviii, 132 pages) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on print version record | ||
| 505 | 8 | |a Whether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures. During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing Regulatory Science for Medical Countermeasure Development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools. Advancing Regulatory Science for Medical Countermeasure Development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations"--Publisher's description | |
| 505 | 8 | |a Introduction -- MCM enterprise and stakeholder perspectives -- Cutting-edge efforts to advance MCM regulatory science -- MCM regulatory science needs for at-risk populations -- Crosscutting themes and future directions -- Closing remarks | |
| 610 | 1 | 4 | |a United States / Food and Drug Administration / Congresses |
| 610 | 2 | 4 | |a United States |b Food and Drug Administration |v Congresses |
| 650 | 7 | |a HEALTH & FITNESS / First Aid |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Allied Health Services / Emergency Medical Services |2 bisacsh | |
| 650 | 4 | |a Disaster Planning / Congresses / organization & administration / United States | |
| 650 | 4 | |a Emergency Medical Services / Congresses / organization & administration / United States | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Emergency management |z United States |x Evaluation |v Congresses | |
| 650 | 4 | |a Disaster medicine |z United States |x Evaluation |v Congresses | |
| 650 | 4 | |a Weapons of mass destruction |x Health aspects |v Congresses | |
| 650 | 4 | |a Chemical agents (Munitions) |v Congresses | |
| 651 | 4 | |a USA | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 700 | 1 | |a Wizemann, Theresa M. |e Sonstige |4 oth | |
| 700 | 1 | |a Altevogt, Bruce M. |e Sonstige |4 oth | |
| 700 | 1 | |a Claiborne, Anne B. |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |b Forum on Drug Discovery, Development, and Translation |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |b Forum on Medical and Public Health Preparedness for Catastrophic Events |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Advancing regulatory science for medical countermeasure development |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=396594 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028463993 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=396594 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=396594 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175401957720064 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043039347 |
| collection | ZDB-4-EBA |
| contents | Whether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures. During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing Regulatory Science for Medical Countermeasure Development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools. Advancing Regulatory Science for Medical Countermeasure Development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations"--Publisher's description Introduction -- MCM enterprise and stakeholder perspectives -- Cutting-edge efforts to advance MCM regulatory science -- MCM regulatory science needs for at-risk populations -- Crosscutting themes and future directions -- Closing remarks |
| ctrlnum | (OCoLC)748588094 (DE-599)BVBBV043039347 |
| dewey-full | 362.18 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.18 |
| dewey-search | 362.18 |
| dewey-sort | 3362.18 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05211nmm a2200625zc 4500</leader><controlfield tag="001">BV043039347</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151120s2011 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309214904</subfield><subfield code="9">0-309-21490-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309214912</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-309-21491-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1283253542</subfield><subfield code="9">1-283-25354-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309214902</subfield><subfield code="9">978-0-309-21490-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309214919</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-309-21491-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781283253543</subfield><subfield code="9">978-1-283-25354-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)748588094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043039347</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.18</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advancing regulatory science for medical countermeasure development</subfield><subfield code="b">workshop summary</subfield><subfield code="c">Theresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Forum on Medical and Public Health PreparadnessforCatastropicEvents, Board on Health Sciences Policy, Institute of Medicine of the National Academies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">Natlional Academies Press</subfield><subfield code="c">©2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xviii, 132 pages)</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on print version record</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Whether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures. During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing Regulatory Science for Medical Countermeasure Development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools. Advancing Regulatory Science for Medical Countermeasure Development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations"--Publisher's description</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Introduction -- MCM enterprise and stakeholder perspectives -- Cutting-edge efforts to advance MCM regulatory science -- MCM regulatory science needs for at-risk populations -- Crosscutting themes and future directions -- Closing remarks</subfield></datafield><datafield tag="610" ind1="1" ind2="4"><subfield code="a">United States / Food and Drug Administration / Congresses</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">United States</subfield><subfield code="b">Food and Drug Administration</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / First Aid</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Allied Health Services / Emergency Medical Services</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Disaster Planning / Congresses / organization & administration / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Emergency Medical Services / Congresses / organization & administration / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Emergency management</subfield><subfield code="z">United States</subfield><subfield code="x">Evaluation</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Disaster medicine</subfield><subfield code="z">United States</subfield><subfield code="x">Evaluation</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Weapons of mass destruction</subfield><subfield code="x">Health aspects</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemical agents (Munitions)</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wizemann, Theresa M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Altevogt, Bruce M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Claiborne, Anne B.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Forum on Drug Discovery, Development, and Translation</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Forum on Medical and Public Health Preparedness for Catastrophic Events</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Advancing regulatory science for medical countermeasure development</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=396594</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028463993</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=396594</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=396594</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043039347 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:15:43Z |
| institution | BVB |
| isbn | 0309214904 0309214912 1283253542 9780309214902 9780309214919 9781283253543 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028463993 |
| oclc_num | 748588094 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource (xviii, 132 pages) illustrations |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | Natlional Academies Press |
| record_format | marc |
| spelling | Advancing regulatory science for medical countermeasure development workshop summary Theresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Forum on Medical and Public Health PreparadnessforCatastropicEvents, Board on Health Sciences Policy, Institute of Medicine of the National Academies Washington, D.C. Natlional Academies Press ©2011 1 online resource (xviii, 132 pages) illustrations txt rdacontent c rdamedia cr rdacarrier Description based on print version record Whether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures. During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing Regulatory Science for Medical Countermeasure Development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools. Advancing Regulatory Science for Medical Countermeasure Development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations"--Publisher's description Introduction -- MCM enterprise and stakeholder perspectives -- Cutting-edge efforts to advance MCM regulatory science -- MCM regulatory science needs for at-risk populations -- Crosscutting themes and future directions -- Closing remarks United States / Food and Drug Administration / Congresses United States Food and Drug Administration Congresses HEALTH & FITNESS / First Aid bisacsh MEDICAL / Allied Health Services / Emergency Medical Services bisacsh Disaster Planning / Congresses / organization & administration / United States Emergency Medical Services / Congresses / organization & administration / United States Medizin Emergency management United States Evaluation Congresses Disaster medicine United States Evaluation Congresses Weapons of mass destruction Health aspects Congresses Chemical agents (Munitions) Congresses USA (DE-588)1071861417 Konferenzschrift gnd-content Wizemann, Theresa M. Sonstige oth Altevogt, Bruce M. Sonstige oth Claiborne, Anne B. Sonstige oth Institute of Medicine (U.S.) Forum on Drug Discovery, Development, and Translation Sonstige oth Institute of Medicine (U.S.) Forum on Medical and Public Health Preparedness for Catastrophic Events Sonstige oth Erscheint auch als Druck-Ausgabe Advancing regulatory science for medical countermeasure development http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=396594 Aggregator Volltext |
| spellingShingle | Advancing regulatory science for medical countermeasure development workshop summary Whether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures. During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing Regulatory Science for Medical Countermeasure Development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools. Advancing Regulatory Science for Medical Countermeasure Development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations"--Publisher's description Introduction -- MCM enterprise and stakeholder perspectives -- Cutting-edge efforts to advance MCM regulatory science -- MCM regulatory science needs for at-risk populations -- Crosscutting themes and future directions -- Closing remarks United States / Food and Drug Administration / Congresses United States Food and Drug Administration Congresses HEALTH & FITNESS / First Aid bisacsh MEDICAL / Allied Health Services / Emergency Medical Services bisacsh Disaster Planning / Congresses / organization & administration / United States Emergency Medical Services / Congresses / organization & administration / United States Medizin Emergency management United States Evaluation Congresses Disaster medicine United States Evaluation Congresses Weapons of mass destruction Health aspects Congresses Chemical agents (Munitions) Congresses |
| subject_GND | (DE-588)1071861417 |
| title | Advancing regulatory science for medical countermeasure development workshop summary |
| title_auth | Advancing regulatory science for medical countermeasure development workshop summary |
| title_exact_search | Advancing regulatory science for medical countermeasure development workshop summary |
| title_full | Advancing regulatory science for medical countermeasure development workshop summary Theresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Forum on Medical and Public Health PreparadnessforCatastropicEvents, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_fullStr | Advancing regulatory science for medical countermeasure development workshop summary Theresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Forum on Medical and Public Health PreparadnessforCatastropicEvents, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_full_unstemmed | Advancing regulatory science for medical countermeasure development workshop summary Theresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Forum on Medical and Public Health PreparadnessforCatastropicEvents, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_short | Advancing regulatory science for medical countermeasure development |
| title_sort | advancing regulatory science for medical countermeasure development workshop summary |
| title_sub | workshop summary |
| topic | United States / Food and Drug Administration / Congresses United States Food and Drug Administration Congresses HEALTH & FITNESS / First Aid bisacsh MEDICAL / Allied Health Services / Emergency Medical Services bisacsh Disaster Planning / Congresses / organization & administration / United States Emergency Medical Services / Congresses / organization & administration / United States Medizin Emergency management United States Evaluation Congresses Disaster medicine United States Evaluation Congresses Weapons of mass destruction Health aspects Congresses Chemical agents (Munitions) Congresses |
| topic_facet | United States / Food and Drug Administration / Congresses United States Food and Drug Administration Congresses HEALTH & FITNESS / First Aid MEDICAL / Allied Health Services / Emergency Medical Services Disaster Planning / Congresses / organization & administration / United States Emergency Medical Services / Congresses / organization & administration / United States Medizin Emergency management United States Evaluation Congresses Disaster medicine United States Evaluation Congresses Weapons of mass destruction Health aspects Congresses Chemical agents (Munitions) Congresses USA Konferenzschrift |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=396594 |
| work_keys_str_mv | AT wizemanntheresam advancingregulatoryscienceformedicalcountermeasuredevelopmentworkshopsummary AT altevogtbrucem advancingregulatoryscienceformedicalcountermeasuredevelopmentworkshopsummary AT claiborneanneb advancingregulatoryscienceformedicalcountermeasuredevelopmentworkshopsummary AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation advancingregulatoryscienceformedicalcountermeasuredevelopmentworkshopsummary AT instituteofmedicineusforumonmedicalandpublichealthpreparednessforcatastrophicevents advancingregulatoryscienceformedicalcountermeasuredevelopmentworkshopsummary |